The success of endosseous implants in human immunodeficiency virus-positive patients receiving antiretroviral therapy A pilot study

The success of endosseous implants in human immunodeficiency virus-positive patients receiving antiretroviral therapy A pilot study

Author Oliveira, Marcio Augusto de Google Scholar
Gallottini, Marina Helena Google Scholar
Pallos, Debora Google Scholar
Maluf, Paulo Sérgio Zaidan Autor UNIFESP Google Scholar
Jablonka, Fernando Google Scholar
Ortega, Karem Lopez Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Background. In a pilot study, the authors aimed to determine the success rate of dental implants placed in patients who were positive for human immunodeficiency virus (HIV) and were receiving different regimens of highly active anti-retroviral therapy (HAART). They considered patients' levels of cluster of differentiation (CD) 4(+) cells and viral load, and they attempted to verify whether patients with baseline biochemical signs of bone mineral density loss could experience osseointegration impairment.Materials and Methods. One of the authors, a dentist, placed dental implants in the posterior mandibles of 40 volunteers, divided into three groups: one composed of HIV-positive patients receiving protease inhibitor (PI)-based HAART; a second composed of HIV-positive patients receiving nonnucleoside reverse transcriptase inhibitor based HAART (without PI); and a control group composed of HIV-negative participants. The authors assessed pen-implant health six and 12 months after implant loading. They analyzed the success of the implants in relation to CD4(+) cell counts, viral load and baseline pyridinoline and deoxypyridinoline values.Results. The authors followed 59 implants for 12 months after loading. Higher baseline levels of pyridinoline and deoxypyridinoline found in HIV-positive participants did not interfere with osseointegration after 12 months of follow-up. Average pen-implant bone loss after 12 months was 0.49 millimeters in group 1, 0.47 mm in group 2, and 0.55 mm in the control group.Conclusions. The placement of dental implants in HIV-positive patients is a reasonable treatment option, regardless of CD4(+) cell count, viral load levels and type of antiretroviral therapy. Longer, follow-up periods are necessary to ascertain the predictability of the long-term success of dental implants in these patients.Clinical Implications. Limited published scientific evidence is available to guide clinicians in regard to possible increased risks associated with dental implant placement in HIV-positive patients.
Keywords Human immunodeficiency virus
AIDS
highly active antiretroviral therapy
dental implants
pyridinoline
deoxypyridinoline
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Grant number FAPESP: 60239-0/2006
Date 2011-09-01
Published in Journal Of The American Dental Association. Chicago: Amer Dental Assoc, v. 142, n. 9, p. 1010-1016, 2011.
ISSN 0002-8177 (Sherpa/Romeo, impact factor)
Publisher Amer Dental Assoc
Extent 687-692
Origin http://dx.doi.org/10.14219/jada.archive.2011.0320
Access rights Closed access
Type Article
Web of Science ID WOS:000294973000010
URI http://repositorio.unifesp.br/11600/44730

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account